N/A N=329 Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial
Cardiac Arrest
Primary: Survival With Good Neurobehavioral Outcome — 48; 48; 85; 76 Participants — p=0.63
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=56 Can Addition of Doxycycline Perioperatively Reduce Propionibacterium Acnes in Shoulder Arthroplasty?
Osteoarthritis
Primary: Bacterial Culture — 14; 15 # Participants with Bacteria in Culture
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
N/A N=10 Ketone Production With Acute Caffeine Intake
Healthy Adults
Primary: Plasma Acetoacetate Concentrations — 26.06; 30.99; 32.10 µmol/L
Phase 2 N=714 Phase II HDM-SPIRE Safety and Efficacy Study
Rhinoconjunctivitis
Primary: Combined Score of Symptoms and Allergy Medication — 1.69; 1.51; 1.40; 1.56 units on a scale
N/A N=54 A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis (MS)
Multiple Sclerosis
Primary: Adherence — 2; 6; 10; 12 Participants
N/A N=78 Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease
Sickle Cell Disease
Primary: Change From Baseline on Disease Self-efficacy Measure at 6 Weeks — 33.2; 33.09 units on a scale — p=0.575
N/A N=28 Combined Application of Electrical Stimulated Antagonist Contraction During Walking (Walking Study)
Knee Osteoarthritis
Primary: Change in Knee Extensor Strength Assessed by Isokinetic Dynamometer. — 9.6; 3.8 Newton-meters (Nm)
Phase 4 N=144 Metabolic Effects of Antipsychotics in Children
Aggression · Attention Deficit-Hyperactivity · Oppositional Defiant Disorder
Primary: Change in DEXA % Body Fat — 1.81; 4.12; 1.66 percent body fat — p=<0.0001
Phase 4 N=16 Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson
Ischemic Heart Disease
Primary: Diagnostic Accuracy of Cardiac PET/MRI Examination — 50; 64; 61; 64 percentage — p=0.35
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
Phase 2 N=10 Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids
Hyperalgesia
Primary: Percent Change From Baseline in Size (Area) of Secondary Hyperalgesia After Cessation of Remifentanil Infusion, a Measure of Opioid-induced Hyperalgesia (OIH). — -28…
N/A N=80 Tailored Self-Management of Temporomandibular Disorders (TMD) Using Health Information Technology
Temporomandibular Joint Dysfunction Syndrome
Primary: Assessing Graded Chronic Pain Severity Evaluation Feasibility of the PACT Program — -12; -19 units on a scale
Phase 3 N=1,012 Ranolazine Implantable Cardioverter-Defibrillator Trial
Ischemic Cardiomyopathy · Nonischemic Cardiomyopathy · Heart Failure
Primary: Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death — 174; 198 Participants — p=0.117
Phase 2 N=25 A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
TTR-mediated Amyloidosis
Primary: Safety and Tolerability Results of Long-term Dosing With ALN-TTRSC (Revusiran) Transthyretin (TTR) Cardiac Amyloidosis Patients. — 25; 22; 18 Participants